This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Balancing the Portfolio

Peter M. Small, MD

JAMA. 1996;276(18):1512-1513.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Tuberculosis (TB) is a killer with impressive credentials. Over the past 2 centuries, it has killed a billion people.¹ Currently it is the leading cause of mortality from a single infectious agent—accounting for 26% of preventable adult deaths in the developing world.² In the coming decade, it is slated to kill at least 30 million people.³

See also p 1502.

The synergy between the epidemics of TB and human immunodeficiency virus (HIV) constitutes a global public health crisis of staggering dimensions. In persons infected with HIV, infection with Mycobacterium tuberculosis is much more likely to progress rapidly to active disease, which is increasingly difficult to diagnose and more complicated to treat.⁴ Globally, TB is now the leading cause of death among persons with acquired immunodeficiency syndrome (AIDS), killing 1 of every 3 people who die with AIDS.³ To date, the dual scourge of TB and . . . [Full Text PDF of this Article]

Author Affiliations
From the Division of Infectious Diseases and Geographic Medicine, Stanford University Medical Center, Stanford, Calif.

Footnotes
Corresponding author: Peter M. Small, MD, Division of Infectious Diseases and Geographic Medicine, Stanford University Medical Center, Stanford, CA 94305 (e-mail: peter@molepi.stanford.edu).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?